Francis, Jose, Barnes, Karen I, Workman, Lesley, Kredo, Tamara, Vestergaard, Lasse S, Hoglund, Richard M, Byakika-Kibwika, Pauline, Lamorde, Mohammed, Walimbwa, Stephen I, Chijioke-Nwauche, Ifeyinwa et al (show 11 more authors)
(2020)
An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64 (5).
e02394-e02319.
Abstract
Treating malaria in HIV-coinfected individuals should consider potential drug-drug interactions. Artemether-lumefantrine is the most widely recommended treatment for uncomplicated malaria globally. Lumefantrine is metabolized by CYP3A4, an enzyme that commonly used antiretrovirals often induce or inhibit. A population pharmacokinetic meta-analysis was conducted using individual participant data from 10 studies with 6,100 lumefantrine concentrations from 793 nonpregnant adult participants (41% HIV-malaria-coinfected, 36% malaria-infected, 20% HIV-infected, and 3% healthy volunteers). Lumefantrine exposure increased 3.4-fold with coadministration of lopinavir-ritonavir-based antiretroviral therapy (ART), while it decreased by 47% with efavirenz-based ART and by 59% in the patients with rifampin-based antituberculosis treatment. Nevirapine- or dolutegravir-based ART and malaria or HIV infection were not associated with significant effects. Monte Carlo simulations showed that those on concomitant efavirenz or rifampin have 49% and 80% probability of day 7 concentrations <200 ng/ml, respectively, a threshold associated with an increased risk of treatment failure. The risk of achieving subtherapeutic concentrations increases with larger body weight. An extended 5-day and 6-day artemether-lumefantrine regimen is predicted to overcome these drug-drug interactions with efavirenz and rifampin, respectively.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | uncomplicated malaria, lumefantrine, human immunodeficiency virus, drug-drug interactions, population pharmacokinetics |
Depositing User: | Symplectic Admin |
Date Deposited: | 04 Mar 2020 08:28 |
Last Modified: | 18 Jan 2023 23:59 |
DOI: | 10.1128/AAC.02394-19 |
Open Access URL: | https://aac.asm.org/content/early/2020/02/11/AAC.0... |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3077614 |